tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Melanoma D008545 69 associated lipids
Hematologic Diseases D006402 3 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Osteoporosis D010024 12 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Kidney Diseases D007674 29 associated lipids
Hematuria D006417 13 associated lipids
Weight Gain D015430 101 associated lipids
Brain Diseases D001927 27 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Ferraresso M et al. Conversion from cyclosporine to tacrolimus for refractory acute rejection in pediatric kidney transplant recipients: a single-center experience. 2001 Nov-Dec Transplant. Proc. pmid:11750525
Garcia CD et al. Renal transplantation in children less than six years old. 2001 Nov-Dec Transplant. Proc. pmid:11750527
Morris-Stiff G et al. Pharmaco-economic study of FK 506 (Prograf) and cyclosporine A Neoral in cadaveric renal transplantation. 1998 Transplant. Proc. pmid:9636521
Yashima J et al. Successful conversion from tacrolimus to cyclosporine after kidney transplantation. 2000 Transplant. Proc. pmid:11119895
Smoter P et al. Risk factors of acute renal failure after orthotopic liver transplantation: single-center experience. 2014 Transplant. Proc. pmid:25380918
Mendez R FK 506 and mycophenolate mofetil in renal transplant recipients: six-month results of a multicenter, randomized dose ranging trial. FK 506 MMF Dose-Ranging Kidney Transplant Study Group. 1998 Transplant. Proc. pmid:9636522
Yuan QS et al. Rescue therapy with tacrolimus in renal graft patients with cyclosporine A-induced hepatotoxicity: a preliminary study. 2000 Transplant. Proc. pmid:11119896
Corry RJ et al. Pancreas transplantation without antibody therapy. 1998 Transplant. Proc. pmid:9532050
Kahl A et al. First results with a quadruple therapy regimen including tacrolimus and mycophenolate mofetil in patients after combined pancreas and kidney transplantation. 1998 Transplant. Proc. pmid:9532149
Sánchez-Fructuoso AI et al. The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients. 2009 Jul-Aug Transplant. Proc. pmid:19715905
Asensio M et al. Experience with tacrolimus as primary immunosuppressor in pediatric liver transplant. 2002 Transplant. Proc. pmid:11959208
Brook NR et al. Prograf produces a molecular environment favoring antifibrosis, an effect reversed by the addition of rapamune. 2005 Jan-Feb Transplant. Proc. pmid:15808577
Mueller AR et al. Increased rejection after liver transplantation in FK 506-treated patients is associated with viral hepatitis C disease. 1994 Transplant. Proc. pmid:7527984
Stock PG et al. Standard sequential immunosuppression with Minnesota antilymphoblast globulin and cyclosporine vs FK 506: a comparison of early nephrotoxicity. 1993 Transplant. Proc. pmid:7679838
Abu-Elmagd KM et al. Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation. 1991 Transplant. Proc. pmid:1721271
Sakr M et al. Effect of renal ischemia on plasma levels of FK 506 in rats. 1992 Transplant. Proc. pmid:1371625
Smit JA et al. Induction of primate TH2 lymphokines to suppress TH1 cells. 1996 Transplant. Proc. pmid:8623334
Kay JE et al. The mechanism of action of FK 506. 1990 Transplant. Proc. pmid:1689914
Cantarovich M et al. Optimal time points for the prediction of the area-under-the-curve in liver transplant patients receiving tacrolimus. 1998 Transplant. Proc. pmid:9636592
Hachida M et al. Combined use of deoxyspergualin and FK 506 for temporary circulatory assist. 1999 Transplant. Proc. pmid:10455968
Harihara Y et al. Correlation between graft size and necessary tacrolimus dose after living-related liver transplantation. 2000 Transplant. Proc. pmid:11120116
van Hooff JP et al. Tacrolimus and glucose metabolism. 1999 Transplant. Proc. pmid:10576044
Santos L et al. New-onset diabetes after transplantation: drug-related risk factors. 2012 Transplant. Proc. pmid:23146462
Torio A et al. Effect of CYP3A51/3 polymorphism on blood pressure in renal transplant recipients. 2012 Transplant. Proc. pmid:23146466
Yoshimura N et al. Combination therapy of tacrolimus (FK506) with azathioprine and steroids in renal transplant recipients. 1998 Transplant. Proc. pmid:9474949
Asano T et al. Increased tacrolimus trough levels in association with severe diarrhea, a case report. 2004 Transplant. Proc. pmid:15518758
Kim SJ et al. Randomized trial of tacrolimus versus cyclosporine in steroid withdrawal in living donor renal transplant recipients. 2004 Transplant. Proc. pmid:15518759
Boran M et al. Determining renal resistive and pulsatility indexes long-term after kidney transplantation in kidney transplant recipients on cyclosporine a-, tacrolimus-, or sirolimus-based regimens. 2014 Transplant. Proc. pmid:24935296
DiLella AG and Craig RJ Characterization of the human FKBP-12 gene and related pseudogenes. 1991 Transplant. Proc. pmid:1721302
Imai K et al. Pancreaticoduodenal allotransplantation with the use of FK 506, cyclosporine, and triple-regimen immunosuppression. 1990 Transplant. Proc. pmid:1697117
Laftavi MR et al. African American renal transplant recipients (RTR) require higher tacrolimus doses to achieve target levels compared to white RTR: does clotrimazole help? 2013 Transplant. Proc. pmid:24314941
Falkiewicz K et al. Tacrolimus decreases tubular phosphate wasting in renal allograft recipients. 2003 Transplant. Proc. pmid:14529892
Reggiani P et al. A "steroid-free" tacrolimus and low-dose mycophenolate mofetil primary immunosuppression does not prevent early acute rejection after liver transplantation. 2005 Transplant. Proc. pmid:15919435
Wilusz M et al. Effect of immunosuppressive therapy on the serum fatty acids of phospholipids fraction in patients after heart transplantation. 2014 Transplant. Proc. pmid:25380928
Ge J et al. Impact of FOXP3 Polymorphisms on the Blood Level of Tacrolimus in Renal Transplant Recipients. Transplant. Proc. pmid:27569929
Kapturczak MH et al. Pharmacology of calcineurin antagonists. 2004 Transplant. Proc. pmid:15041303
Yang SS et al. A single center, open-label, randomized pilot study to evaluate the safety and efficacy of tacrolimus modified release, Advagraf, versus tacrolimus twice daily, Prograf, in stable renal recipients (single). 2015 Transplant. Proc. pmid:25891697
Jin KB et al. Effects of tacrolimus on antioxidant status and oxidative stress in glioma cells. 2008 Transplant. Proc. pmid:18929850
Hranjec T et al. Benign transient hyperphosphatasemia associated with Epstein-Barr virus enteritis in a pediatric liver transplant patient: a case report. 2008 Transplant. Proc. pmid:18589195
Grossi P et al. Infectious complications in experimental small bowel transplantation. 1994 Transplant. Proc. pmid:7518155
Utsunomiya H et al. Effect of FK 506 on orthotopic small bowel transplantation in rats. 1992 Transplant. Proc. pmid:1376521
Tsugita M et al. Prevention of sensitization and hyperacute rejection in liver and heart xenografts by FK 506 plus donor antigens. 1995 Transplant. Proc. pmid:7533393
D'Alessandro AM et al. FK 506 rescue therapy for resistant rejection episodes in liver transplant recipients. 1991 Transplant. Proc. pmid:1721335
Varo E et al. Alternative immunosuppression for acute renal failure in liver transplantation: role of ultra-low dose tacrolimus and basiliximab. 2002 Transplant. Proc. pmid:12176471
Daoud AJ et al. A comparison of the safety and efficacy of mycophenolate mofetil, prednisone and cyclosporine and mycophenolate mofetil, and prednisone and tacrolimus. 1998 Transplant. Proc. pmid:9865303
Braun F et al. How to handle mycophenolate mofetil in combination with tacrolimus? 1998 Transplant. Proc. pmid:9865309
Zegarska J et al. Tacrolimus Metabolite M-III May Have Nephrotoxic and Myelotoxic Effects and Increase the Incidence of Infections in Kidney Transplant Recipients. 2016 Transplant. Proc. pmid:27496443
Yuan-Xin L et al. Preliminary experience with alemtuzumab induction therapy combined with maintenance low-dose tacrolimus monotherapy in small-bowel transplantation in China. 2010 Jan-Feb Transplant. Proc. pmid:20172275
Altaca G et al. Effect of low-dose calcineurin inhibitors on acute rejection and graft survival. 2002 Transplant. Proc. pmid:12270320
Colak T et al. Effect of conversion from cyclosporine to tacrolimus on lipid profiles in renal transplant recipients. 2002 Transplant. Proc. pmid:12270321
Woodside KJ et al. Conversion from cyclosporine to tacrolimus results in improved creatinine but does not alter lipid profile. 2005 Transplant. Proc. pmid:15919491
Marqués E et al. Development of lymphoproliferative disease after liver transplantation. 2008 Transplant. Proc. pmid:19010169
Squifflet JP et al. Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study. 2002 Transplant. Proc. pmid:12176495
Sánchez-Pérez B et al. Influence of immunosuppression and effect of hepatitis C virus on new onset of diabetes mellitus in liver transplant recipients. 2008 Transplant. Proc. pmid:19010171
Ye Q et al. Persistence of donor cells and incidence of graft-versus-host disease after simultaneous small bowel and bone marrow transplantation. 1996 Transplant. Proc. pmid:8907895
Waller JR et al. Primary immunosuppression with tacrolimus is associated with a reduction in renal allograft fibrosis compared with neoral therapy. 2002 Transplant. Proc. pmid:12176496
Kamei T et al. Established intraportal islet allograft is rejected despite the acceptance of donor-specific second cardiac allograft. 1992 Transplant. Proc. pmid:1281579
Ribes D et al. Combined use of tacrolimus and sirolimus in de novo renal transplant patients: current data. 2005 Jul-Aug Transplant. Proc. pmid:16182816
Woo J et al. FK 506 treatment following syngeneic bone marrow transplantation does not inhibit clonal deletion of V beta 5+ or V beta 11+ T cells. 1992 Transplant. Proc. pmid:1281583
Offner G et al. FK 506 in a 14-year-old renal allograft recipient with cyclosporine-related liver nephrotoxicity: 1-year follow-up. 1991 Transplant. Proc. pmid:1721366
Kociszewska-Najman B et al. Congenital Infections in Neonates of Women With Liver or Kidney Transplants. 2016 Transplant. Proc. pmid:27496446
Imai K et al. Histopathological study of canine pancreaticoduodenal allotransplantation with FK506, cyclosporine, and triple regimen immunosuppression. 1991 Transplant. Proc. pmid:1703347
Japanese study of FK 506 on kidney transplantation: the benefit of monitoring the whole blood FK 506 concentration. Japanese FK 506 Study Group. 1991 Transplant. Proc. pmid:1721367
Starzl TE et al. Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. 1991 Transplant. Proc. pmid:1703351
Hattori R et al. FK 506 in cadaveric kidney transplantation from non-heart-beating donors. 1998 Transplant. Proc. pmid:9838666
Fischer L et al. Hepatitis G virus infection in liver transplant recipients. 1999 Feb-Mar Transplant. Proc. pmid:10083208
Goller AL et al. Loss of serum bicarbonate after discordant liver xenotransplantation. 2000 Transplant. Proc. pmid:10936383
Scott-Douglas N et al. Treatment of acute renal transplant rejection with FK 506 in patients on cyclosporine after failure of standard antirejection therapy. 1996 Transplant. Proc. pmid:8962226
Boots JM et al. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. 2002 Transplant. Proc. pmid:12176542
Cho JH et al. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients. 2012 Transplant. Proc. pmid:22310591
Suzuki H et al. Spleen grafting might induce transplantation tolerance in rats. 1995 Transplant. Proc. pmid:7536973
Moutabarrik A et al. Use of FK 506 in kidney transplantation. 1993 Transplant. Proc. pmid:7685946
Nakajima K et al. Effects of 15-deoxyspergualin and FK506 on the histology and survival of hamster-to-rat cardiac xenotransplantation. 1989 Transplant. Proc. pmid:2468223
Janezic AL et al. Alternatively spliced variants of IL-2 mRNA in sequential transplant kidney core needle biopsies. 2001 Feb-Mar Transplant. Proc. pmid:11266873
Opelz G New immunosuppressants and HLA matching. 2001 Feb-Mar Transplant. Proc. pmid:11266911
Fu F et al. Systemic administration of CTLA4-Ig or anti-CD40 ligand antibody inhibits second-set rejection of mouse liver allografts. 1999 Feb-Mar Transplant. Proc. pmid:10083555
Tatekawa Y et al. Intragraft expression of p38 in rat small bowel transplantation. 2000 Transplant. Proc. pmid:10995948
Karamperis N et al. Comparison of the pharmacokinetics of tacrolimus and cyclosporine at equivalent molecular doses. 2003 Transplant. Proc. pmid:12826146
Budde K et al. Long-term outcome of tacrolimus rescue therapy in late rejection after renal transplantation. 1998 Transplant. Proc. pmid:9723280
Dopazo C et al. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin with rapamycin plus tacrolimus in liver transplant patient. 2009 Transplant. Proc. pmid:19376416
Baran DA et al. Can initial tacrolimus trough levels be predicted from clinical variables? 2004 Transplant. Proc. pmid:15621157
Land W et al. Tacrolimus versus cyclosporine in primary simultaneous pancreas-kidney transplantation: preliminary results at 1 year of a large multicenter trial. 2002 Transplant. Proc. pmid:12176625
El-Safa EA et al. Paradoxical response to tacrolimus assessed by interleukin-2 gene expression. 2006 Transplant. Proc. pmid:17175263
Langrehr JM et al. FK 506 inhibits nitric oxide production by cells infiltrating sponge matrix allografts. 1991 Transplant. Proc. pmid:1721430
Hayakawa K et al. Maintenance of unresponsiveness by short-term pulse therapy with FK 506 in rat transplantation. 1996 Transplant. Proc. pmid:8658904
Moura Neto A et al. Frequency of Thyroid Dysfunction in Patients With Diabetes Mellitus Before and After Liver Transplantation. 2018 Transplant. Proc. pmid:29661439
Zeevi A et al. Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. 1987 Transplant. Proc. pmid:2445073
Sperschneider H A large, multicentre trial to compare the efficacy and safety of tacrolimus with cyclosporine microemulsion following renal transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267291
Shapiro R Tacrolimus in solid organ transplantation: an update. 1999 Transplant. Proc. pmid:10500545
Martins L et al. Conversion to tacrolimus in case-problem kidney transplant recipients under cyclosporine-based immunosuppression. 2000 Transplant. Proc. pmid:11134735
Hanack U et al. Is there a different impact of cyclosporine versus tacrolimus on delayed graft function after kidney transplantation? 1998 Transplant. Proc. pmid:9723477
Mohsin N et al. Low tacrolimus dose requirements in renal transplant recipients in the omani population: implications for pharmacogenetics? 2005 Transplant. Proc. pmid:16213259
Deguchi K et al. Effects of FK 506 on acute experimental allergic encephalomyelitis. 1991 Transplant. Proc. pmid:1721461
Bolton C The ability of myelin basic protein-sensitised leukocytes to adoptively transfer experimental allergic encephalomyelitis following coculture with FK 506, cyclosporine, or prednisolone. 1991 Transplant. Proc. pmid:1721462
Lee CM et al. Monotherapy with tacrolimus for heart and liver transplant: a case report. 2014 Transplant. Proc. pmid:24767396
Lo A et al. Ganciclovir prophylaxis for cytomegalovirus infection in simultaneous kidney-pancreas transplant recipients receiving tacrolimus, mycophenolate mofetil, and prednisone. 2001 Feb-Mar Transplant. Proc. pmid:11267516
Calne RY Immunosuppression for organ grafting. 1991 Transplant. Proc. pmid:1714646
Malinowski K et al. Effect of different anti-rejection regimens on the expression of differentiation and activation markers on the surface of host lymphocytes. 2000 Transplant. Proc. pmid:10856579
Matsumoto S et al. ET-Kyoto ductal injection and density-adjusted purification combined with potent anti-inflammatory strategy facilitated single-donor islet transplantation: case reports. 2010 Jul-Aug Transplant. Proc. pmid:20692433
Morris RE et al. Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions. 1991 Transplant. Proc. pmid:1703698